Abstract:Abstract IMPORTANCE Genetic diseases are a leading cause of childhood mortality. Whole genome sequencing (WGS) and whole exome sequencing (WES) are relatively new methods for diagnosing genetic diseases. OBJECTIVES Compare the diagnostic sensitivity (rate of causative, pathogenic or likely pathogenic genotypes in known disease genes) and rate of clinical utility (proportion in whom medical or surgical management was changed by diagnosis) of WGS, WES, and chromosomal microarrays (CMA) in children with suspected genetic diseases. DATA SOURCES AND STUDY SELECTION Systematic review of the literature (January 2011 - August 2017) for studies of diagnostic sensitivity and/or clinical utility of WGS, WES, and/or CMA in children with suspected genetic diseases. 2% of identified studies met selection criteria. DATA EXTRACTION AND SYNTHESIS Two investigators extracted data independently following MOOSE/PRISMA guidelines. MAIN OUTCOMES AND MEASURES Pooled rates and 95% Cl were estimated with a random-effects model. Metaanalysis of the rate of diagnosis was based on test type, family structure, and site of testing. RESULTS In 36 observational series and one randomized control trial, comprising 20,068 children, the diagnostic sensitivity of WGS (0.41, 95% Cl 0.34-0.48, I 2 =44%) and WES (0.35, 95% Cl 0.31-0.39, I 2 =85%) were qualitatively greater than CMA (0.10, 95% Cl 0.08-0.12, I 2 =81%). Subgroup meta-analyses showed that the diagnostic sensitivity of WGS was significantly greater than CMA in studies published in 2017 ( P <.0001, I 2 =13% and I 2 =40%, respectively), and the diagnostic sensitivity of WES was significantly greater than CMA in studies featuring within-cohort comparisons ( P <001, I 2 =36%). Evidence for a significant difference in the diagnostic sensitivity of WGS and WES was lacking. In studies featuring within-cohort comparisons of singleton and trio WGS/WES, the likelihood of diagnosis was significantly greater for trios (odds ratio 2.04, 95% Cl 1.62-2.56, I 2 =12%; P <.0001). The diagnostic sensitivity of WGS/WES with hospital-based interpretation (0.41, 95% Cl 0.38-0.45, I 2 =50%) was qualitatively higher than that of reference laboratories (0.28, 95% Cl 0.24-0.32, I 2 =81%); this difference was significant in meta-analysis of studies published in 2017 ( P =.004, I 2 =34% and I 2 =26%, respectively). The rates of clinical utility of WGS (0.27, 95% Cl 0.17-0.40, I 2 =54%) and WES (0.18, 95% Cl 0.13-0.24, I 2 -77%) were higher than CMA (0.06, 95% Cl 0.05-0.07, I 2 =42%); this difference was significant in meta-analysis of WGS vs CMA ( P <.0001). CONCLUSIONS AND RELEVANCE In children with suspected genetic diseases, the diagnostic sensitivity and rate of clinical utility of WGS/WES were greater than CMA. Subgroups with higher WGS/WES diagnostic sensitivity were trios and those receiving hospital-based interpretation. WGS/WES should be considered a first-line genomic test for children with suspected genetic diseases. Key Points Question What is the relative diagnostic sensitivity and clinical utility of different genome tests in children with suspected genetic diseases? Findings Whole genome sequencing had greater diagnostic sensitivity and clinical utility than chromosomal microarrays. Testing parent-child trios had greater diagnostic sensitivity than proband singletons. Hospital-based testing had greater diagnostic sensitivity than reference laboratories. Meaning Trio genomic sequencing is the most sensitive diagnostic test for children with suspected genetic diseases.

The usefulness of whole-exome sequencing in routine clinical practice

Clinical application of whole-exome sequencing across clinical indications

Exome and Whole-Genome Sequencing As Clinical Tests: a Transformative Practice in Molecular Diagnostics.

Promises, pitfalls and practicalities of prenatal whole exome sequencing

Comparison of medical management and genetic counseling options pre- and post-whole exome sequencing for patients with positive and negative results.

Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Clinical exome sequencing for fetuses with ultrasound abnormalities and a suspected Mendelian disorder

Real-World Evaluation of a Population Germline Genetic Screening Initiative for Family Medicine Patients

Clinical use of whole exome sequencing in children with developmental delay/intellectual disability

Expanded carrier screening for inherited genetic disease using exome and genome sequencing

Clinical Interpretation and Implications of Whole-Genome Sequencing

Use of Exome Sequencing for Infants in Intensive Care Units: Ascertainment of Severe Single-Gene Disorders and Effect on Medical Management.

A review of consensus statements, practice resources, standards and guidelines for clinical applications of next-generation sequencing technologies in the United States

Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test

The application of whole-exome sequencing in the early diagnosis of rare genetic diseases in children: a study from Southeastern China

Whole exome sequencing as a diagnostic adjunct to clinical testing in fetuses with structural abnormalities

Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases

A meta-analysis of the diagnostic sensitivity and clinical utility of genome sequencing, exome sequencing and chromosomal microarray in children with suspected genetic diseases

Implementation of whole-exome sequencing for pharmacogenomics profiling and exploring its potential clinical utilities

Advantages and Perils of Clinical Whole-Exome and Whole-Genome Sequencing in Cardiomyopathy